Aktienanalyse zu Alexandria Real Estate Equities, Inc (ARE)AREAlexandria Real Estate Equities, Inc

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).

Alexandria Real Estate Equities Inc (ARE) is currently priced at $51.57, which is slightly below the average analyst price target of $52.86. However, the stock has experienced a significant 36.26% decline over the past year, indicating potential volatility. The RSI is at 50.199, suggesting the stock is neither overbought nor oversold, which may be a sign to hold rather than buy at this moment.

12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.